ABBV vs S&P 500: Which Stock to Watch

2026 Update: ABBV vs. S&P 500 Through October 26

This ABBV vs. S&P 500 comparison was updated on October 27, 2026. Market data and trailing returns are through the October 26 close, the latest completed US trading session. AbbVie's latest available financial results at the editorial cutoff were for the quarter ended June 30, 2026. Third-quarter results were scheduled for October 30 and are not estimated here.

ABBV closed at $286.74, with a 52-week range of $190.75 to $291.40 and a market capitalization of approximately $506.7 billion. Yahoo Finance reported a five-year monthly beta of 0.23, trailing EPS of $3.54, and a trailing P/E ratio of 81.00. Its indicated annual dividend was $6.92 per share, equal to a forward yield of approximately 2.41% at the closing price.

Yahoo Finance's common-endpoint comparison showed ABBV outperforming the S&P 500 over every displayed period:

The figures may include dividends or other distributions where applicable. Past outperformance does not establish that ABBV will lead the index in future periods.

AbbVie's Q2 2026 net revenue increased 10.2% year over year to $16.990 billion. Adjusted diluted EPS rose 22.9% to $3.65. Skyrizi and Rinvoq continued to offset Humira's decline, generating quarterly net revenue of $5.505 billion and $2.525 billion, respectively, while Humira revenue fell to $756 million.

Eligible users can review current information on the Bybit TradFi ABBV page and, where available, explore ABBV real stock trading. Eligibility, market hours, fees, custody, corporate actions, and shareholder treatment depend on the relevant product terms and jurisdiction.

The former article used 2025 labels and contained unresolved figures. The comparison below replaces those fields with dated values and does not retain the old allocation recommendations.

ABBV vs. S&P 500: Key Differences

AbbVie is a single biopharmaceutical company. The S&P 500 is a diversified index of leading US-listed companies. An investor cannot buy an index directly, so practical S&P 500 exposure normally comes through a tracking fund or another financial product.

ABBV offers direct exposure to AbbVie's products and pipeline. S&P 500 exposure includes a small indirect position in ABBV while the company remains an index constituent, alongside hundreds of other businesses.

ABBV vs. S&P 500 Historical Returns

The updated return figures use the same October 26, 2026 endpoint. This avoids combining an old ABBV price with a newer index level or comparing price return for one asset with total return for the other.

What a $10,000 Investment Would Illustrate

Applying the reported returns mechanically gives the following hypothetical values before fees and taxes:

These values are illustrations, not account statements. The actual outcome depends on the investment product, reinvestment, fees, taxes, execution price, and holding dates.

ABBV's five-year result benefited from strong share-price appreciation and dividends during the post-Humira transition. A large historical gain can also raise the valuation investors are being asked to pay for future earnings.

ABBV Dividend vs. the S&P 500

At the October 26 cutoff, ABBV's indicated annual dividend was $6.92 per share, or $1.73 per quarter, producing a forward yield of approximately 2.41% at the closing price.

Dividend yield moves inversely with the share price when the payment is unchanged. ABBV's yield therefore fell below the 3.5% to 4.5% range cited in the older article largely because the stock price rose substantially. A lower current yield does not by itself mean the cash dividend was cut.

AbbVie has raised its dividend annually since becoming an independent company in 2013. Its classification in dividend-growth indices incorporates the dividend history associated with Abbott Laboratories before the spin-off. Index eligibility and methodology should be verified with the index provider rather than inferred solely from AbbVie's age as a standalone company.

Future dividends are not guaranteed. The board considers cash flow, debt, acquisitions, research spending, business performance, and other capital priorities before declaring payments.

An S&P 500 tracking product may distribute dividends received from its holdings or reinvest them according to its structure. Its yield will differ from ABBV's and can change with index composition, constituent payments, fees, and market price.

AbbVie's Business Engine After Humira

Skyrizi and Rinvoq

Skyrizi and Rinvoq are the central growth products in AbbVie's immunology portfolio. In Q2 2026:

• Skyrizi net revenue rose 24.4% year over year to $5.505 billion.
• Rinvoq net revenue rose 24.5% to $2.525 billion.
• Combined quarterly revenue reached $8.030 billion.

Their growth has more than offset the remaining quarterly Humira revenue in absolute terms. Continued performance depends on approved indications, physician adoption, reimbursement, safety, competing therapies, and future patent protection.

Humira Biosimilar Competition

Humira was once AbbVie's largest product. US biosimilar competition began in 2023, reducing price and market share. Q2 2026 global Humira revenue declined 35.9% year over year to $756 million.

The transition is no longer a simple question of whether Humira will decline; that decline is well established. The current question is whether growth across immunology, neuroscience, oncology, and other products can continue to exceed the lost Humira revenue.

Other Portfolios

Q2 2026 neuroscience revenue grew 20.3% to $3.228 billion, supported by products including Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev. Oncology revenue declined 1.5% to $1.650 billion, while aesthetics revenue increased 0.3% to $1.282 billion.

This mix provides more diversification than AbbVie had when Humira dominated its business. It also introduces additional clinical, integration, competition, and execution risks.

AbbVie Q2 2026 Financial Snapshot

AbbVie updated its full-year 2026 adjusted diluted EPS guidance to $13.87 to $14.07. The guidance included a $0.14 expected dilutive effect from the proposed Apogee Therapeutics acquisition and a $0.58 unfavorable year-to-date effect from acquired in-process research and development and milestone expense.

Adjusted figures can help explain underlying operations but should be read alongside GAAP results and the company's reconciliation. Acquisition-related costs and amortization may be excluded from adjusted EPS even though acquisitions require real capital.

ABBV Risk Compared With the S&P 500

Product and Patent Concentration

Pharmaceutical revenue can change rapidly after patent expiry, biosimilar entry, safety findings, reimbursement changes, or a competing product launch. Skyrizi and Rinvoq reduce dependence on Humira but create a new concentration in two major immunology products.

Clinical and Regulatory Risk

Drug candidates can fail during clinical trials or receive narrower labels than expected. Approved products remain subject to safety monitoring, manufacturing standards, advertising rules, and regulatory action.

Pricing and Reimbursement Risk

Government negotiation, insurer formularies, rebates, and international price controls affect the net price AbbVie receives. High reported product sales do not remove pressure from payers seeking lower costs.

Acquisition and Debt Risk

AbbVie has used acquisitions to expand neuroscience, oncology, aesthetics, and its pipeline. Transactions may add future revenue but also require cash, debt, integration, and further research investment. The proposed Apogee transaction was valued at approximately $10.9 billion.

Index Risk

The S&P 500 reduces dependence on one company's medicines, but it remains exposed to recessions, interest rates, valuation compression, and concentration among its largest holdings. Diversification limits company-specific risk; it does not prevent market losses.

ABBV Valuation and Analyst Targets

At $286.74, ABBV traded at a trailing P/E ratio of 81.00 based on GAAP trailing EPS of $3.54. Acquisition-related accounting and other specified charges can make the GAAP multiple look very different from a multiple based on adjusted EPS.

Investors should not switch between GAAP and adjusted figures without labeling the measure. A lower adjusted P/E does not erase acquisition costs, and a high GAAP P/E does not necessarily describe recurring cash generation on its own.

Yahoo Finance displayed analyst targets of $200 at the low end, $284.79 on average, and $328 at the high end. The October 26 closing price was slightly above the average target, illustrating why a consensus target should not be treated as a guaranteed floor or a fixed year-end forecast.

Portfolio Role Without Prescribed Allocations

An individual stock and a diversified index solve different problems. ABBV may be researched for company-specific exposure and dividend income, while an S&P 500 product spreads capital across many businesses.

Holding both increases AbbVie's total portfolio weight above its index representation. Whether that concentration is appropriate depends on the investor's existing holdings, obligations, time horizon, liquidity needs, tax position, knowledge, and capacity for loss. This article does not prescribe a 5%, 10%, or any other allocation.

Experienced traders may also review the ABBVUSDT perpetual market, where available. A perpetual contract is a derivative that provides price exposure; it does not represent ownership of AbbVie shares and does not provide dividends, voting rights, or other shareholder rights. Leverage, liquidation, funding payments, basis differences, and rapid price changes can cause substantial losses.

ABBV vs. S&P 500: Frequently Asked Questions

Has ABBV outperformed the S&P 500?

Yes over the displayed periods through October 26, 2026. ABBV led the S&P 500 year to date and over one, three, and five years using Yahoo Finance's common-endpoint comparison. Past performance does not predict future results.

What was ABBV's dividend yield in October 2026?

The indicated annual dividend was $6.92 per share, equal to a forward yield of approximately 2.41% at the October 26 closing price of $286.74.

Is ABBV less risky than the S&P 500?

ABBV's five-year monthly beta of 0.23 indicated low historical market sensitivity under that calculation. It does not capture every product, clinical, regulatory, acquisition, or patent risk. ABBV remains a concentrated single-company investment.

What drugs are replacing Humira revenue?

Skyrizi and Rinvoq are the main immunology growth products. Their combined Q2 2026 revenue was $8.030 billion, compared with $756 million from Humira.

Is ABBV already included in the S&P 500?

Yes. An S&P 500 tracking product already provides indirect ABBV exposure while AbbVie remains an index constituent.

Does an ABBV perpetual provide dividends?

No. A perpetual contract is a derivative and does not provide share ownership, dividends, voting rights, or other shareholder rights.

Conclusion

ABBV outperformed the S&P 500 across the updated periods through October 26, 2026. Strong Skyrizi and Rinvoq growth, a rising cash dividend, and broader portfolio performance supported the result as Humira declined.

The comparison is not a permanent verdict. AbbVie remains exposed to product concentration, clinical and regulatory outcomes, pricing pressure, acquisitions, and valuation. The S&P 500 provides wider diversification but still carries broad-market risk.

Sources and cutoffs: Market price, range, market capitalization, beta, valuation, dividend, analyst targets, and return comparisons are from Yahoo Finance ABBV through October 26, 2026. Financial, portfolio, and guidance data are from AbbVie's Q2 2026 financial results, published July 31, 2026. Q3 results were scheduled for October 30 and were not available at the October 27 editorial cutoff.

Disclaimer: This article is for informational and educational purposes only. It is not financial, investment, legal, tax, or trading advice. Historical performance does not guarantee future results, and both individual stocks and diversified funds can lose value.